Patents Issued in December 28, 2017
  • Publication number: 20170369548
    Abstract: A two-chain insulin analogue contains Aspartic Acid at position B10 and penta-fluoro-Phenylalanine at position B24, optionally Histidine or Glutamic Acid at position A8, optionally additional substitutions or modifications at positions A13 and/or A14 and/or B28 and/or B29. The analogue may be an analogue of a mammalian insulin, such as human insulin, may optionally include (i) N-terminal deletion of one, two or three residues from the B chain, (ii) a mono-peptide or dipeptide C-terminal extension of the B-chain containing at least one acidic residue, and (iii) other modifications known in the art to enhance the stability of insulin. Fomulations of the above analogues at successive strengths U-100 to U-1000 in soluble solutions at least pH value in the range 7.0-8.0 in the absence or presence of zinc ions at a molar ratio of 0.00-0.10 zinc ions per insulin analogue monomer.
    Type: Application
    Filed: January 20, 2016
    Publication date: December 28, 2017
    Inventor: Michael WEISS
  • Publication number: 20170369549
    Abstract: The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 region are mutated. The mutant molecules of the invention may also include a second amino acid sequence which increases the solubility of the mutant molecule.
    Type: Application
    Filed: August 4, 2017
    Publication date: December 28, 2017
    Inventors: Robert James PEACH, Joseph Naemura, Peter S. Linsley, Jurgen Bajorath
  • Publication number: 20170369550
    Abstract: The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising an antigen-binding domain, wherein the antigen-binding domain of the first CAR binds to CD19 and the antigen-binding domain of the second CAR binds to CD22.
    Type: Application
    Filed: December 23, 2015
    Publication date: December 28, 2017
    Inventors: Martin Pulé, Shaun Cordoba, Shimobi Onuoha, Simon Thomas
  • Publication number: 20170369551
    Abstract: Provided herein are methods, compositions, and kits for treating IgA nephropathy and Henoch-Schönlein purpura nephritis using BAFF inhibitors, including blisibimod.
    Type: Application
    Filed: June 23, 2017
    Publication date: December 28, 2017
    Inventors: Renee MARTIN, James PENNINGTON, Colin HISLOP, Charles OLSON
  • Publication number: 20170369552
    Abstract: Fusion proteins containing a PDGF binding portion, a VEGF binding portion, and an Fc antibody region are described. Also described are nucleic acids encoding the fusion proteins, compositions comprising the fusion proteins, and methods of using the fusion proteins for treating or preventing clinical conditions characterized by abnormal angiogenesis, such as vascular permeability, edema or inflammation.
    Type: Application
    Filed: March 10, 2016
    Publication date: December 28, 2017
    Inventors: Kevin ZEN, Pei-Tzu WU, Jeng-Horng HER, Huang-Tsu CHEN, Jiun-Shyang LEOU, Ching-Hsuan HSU
  • Publication number: 20170369553
    Abstract: The present invention relates to a method for preparing a TNFR-Fc fusion protein mixture comprising a target content of hydrophobic chromatogram peak 3, and to a method for adjusting a content of hydrophobic chromatogram peak 3. Specifically, the present invention relates to (a) a method for preparing a TNFR-Fc fusion protein mixture using a hydrophobic interaction chromatograph medium containing an aromatic functional group, which is pre-equilibrated with an equilibration buffer comprising sodium chloride or ammonium sulfate, and a sample comprising a TNFR-Fc fusion protein mixture liquid produced from mammalian cells, and to a method for adjusting the content of hydrophobic chromatogram peak 3 by hydrophobic chromatography using an equilibration buffer containing a predetermined concentration of sodium chloride or ammonium sulfate.
    Type: Application
    Filed: December 29, 2015
    Publication date: December 28, 2017
    Applicant: LG CHEM, LTD.
    Inventors: Sang Woo PARK, Hwa Young LEE, Soon Woong CHOI, Chul Ho JUNG
  • Publication number: 20170369554
    Abstract: Factor VIII variants and methods of use thereof are disclosed.
    Type: Application
    Filed: June 5, 2017
    Publication date: December 28, 2017
    Applicant: The Children's Hospital of Philadelphia
    Inventors: Valder ARRUDA, Rodney M. CAMIRE, Nicholas IACOBELLI
  • Publication number: 20170369555
    Abstract: The present invention provides a fibronectin type III (Fn3) molecule, wherein the Fn3 contains a stabilizing mutation. The present invention also provides Fn3 polypeptide monobodies, nucleic acid molecules encoding monobodies, and variegated nucleic acid libraries encoding such monobodies. Also provided are methods of preparing a Fn3 polypeptide monobody, and kits to perform the methods.
    Type: Application
    Filed: February 16, 2016
    Publication date: December 28, 2017
    Applicant: Research Corporation Technologies, Inc.
    Inventor: Shohei Koide
  • Publication number: 20170369556
    Abstract: Disclosed are compositions and methods related to recombinant cells expressing microRNA and an immunoglobulin gene.
    Type: Application
    Filed: December 22, 2015
    Publication date: December 28, 2017
    Inventors: Ralph A. Tripp, Wu Weilin
  • Publication number: 20170369557
    Abstract: Methods useful in constructing libraries that collectively display and/or express members of diverse families of peptides, polypeptides or proteins and the libraries produced using those methods. Methods of screening those libraries and the peptides, polypeptides or proteins identified by such screens.
    Type: Application
    Filed: June 2, 2017
    Publication date: December 28, 2017
    Applicant: Dyax Corp.
    Inventors: Robert Charles Ladner, Edward H. Cohen, Horacio G. Nastri, Kristin L. Rookey, Rene Hoet, Hendricus Renerus Jacobus Mattheus Hoogenboom
  • Publication number: 20170369558
    Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.
    Type: Application
    Filed: July 27, 2017
    Publication date: December 28, 2017
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Serv, University of Washington
    Inventors: John Mascola, Richard Wyatt, Xueling Wu, Yuxing Li, Carl-Magnus Hogerkorp, Mario Roederer, Zhi-yong Yang, Gary Nabel, Peter Kwong, Tongqing Zhou, Mark Connors, William Schief
  • Publication number: 20170369559
    Abstract: Methods of treating Alzheimer's Disease (AD) in patients suffering from mild to moderate AD, including ApoE4 positive patients and patients suffering from mild AD are provided. Also provided are methods of selecting or identifying patients for treatment with an anti-Abeta antibody. Methods include the use of prognostic and/or predictive biomarkers.
    Type: Application
    Filed: August 17, 2016
    Publication date: December 28, 2017
    Applicant: Genentech, Inc.
    Inventor: Robert Graham
  • Publication number: 20170369560
    Abstract: Provided are novel human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.
    Type: Application
    Filed: February 8, 2017
    Publication date: December 28, 2017
    Applicants: Biogen MA Inc., Biogen International Neuroscience GmbH
    Inventors: Paul H. Weinreb, Feng Chen, Ellen A. Garber Stark, Jan Grimm, Fabio Montrasio
  • Publication number: 20170369561
    Abstract: The present invention relates to compositions and methods for diagnosing and treating diseases, disorders or conditions associated with dysregulated expression of GPC3. The invention provides novel antibodies that specifically bind to glypican-3 (GPC3). The invention also relates to a fully human chimeric antigen receptor (CAR) wherein the CAR is able to target GPC3.
    Type: Application
    Filed: September 1, 2017
    Publication date: December 28, 2017
    Inventor: David Kaplan
  • Publication number: 20170369562
    Abstract: The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and use of the compositions in methods for treating or preventing complement-associated disorders. In some embodiments, the inhibitor is chronically administered to patients. In some embodiments, the inhibitor is administered to a patient in an amount and with a frequency to maintain systemic complement inhibition and prevent breakthrough. In some embodiments, the compositions contain an antibody, or antigen-binding fragment thereof, that binds to a human complement component C5 protein or a fragment of the protein such as C5a or C5b.
    Type: Application
    Filed: September 11, 2017
    Publication date: December 28, 2017
    Inventors: Russell P. ROTHER, Camille Bedrosian, Stephen P. Squinto, Leonard Bell
  • Publication number: 20170369563
    Abstract: Disclosed herein are single domain serum albumins binding proteins with improved thermal stability, binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single domain serum albumin binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Application
    Filed: September 14, 2017
    Publication date: December 28, 2017
    Inventors: Robert B. DUBRIDGE, Bryan D. LEMON, Richard J. AUSTIN, Luke EVNIN, Jeanmarie GUENOT
  • Publication number: 20170369564
    Abstract: Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.
    Type: Application
    Filed: January 15, 2016
    Publication date: December 28, 2017
    Applicant: Genentech, Inc.
    Inventors: Manuel Baca, James A. Wells, Leonard G. Presta, Henry B. Lowman, Yvonne Man-yee Chen
  • Publication number: 20170369565
    Abstract: A method of preparing a canine antibody suitable for use in the therapeutic treatment of a canine is provided. In particular, there is provided immunoglobulins which can be selected for the characteristic of whether they mediate downstream complement mediated immune activation when bound to a target antigen. Canine derived antibodies comprising specific heavy chain isotypes are provided. The invention extends to the use of the immunoglobulins of the invention in methods of treating conditions such as pain, inflammatory conditions and cancerous conditions in a canine.
    Type: Application
    Filed: January 24, 2017
    Publication date: December 28, 2017
    Applicant: NEXVET AUSTRALIA PTY LTD
    Inventor: David Gearing
  • Publication number: 20170369566
    Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: May 23, 2017
    Publication date: December 28, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
  • Publication number: 20170369567
    Abstract: The present disclosure relates to methods for selectively reducing CysL97 in a preparation of IL-17 antibodies or antigen binding fragments thereof (e.g., a preparation of secukinumab antibodies) that have been recombinantly produced by mammalian cells. Also provided are purified preparations of IL-17 antibodies or antigen binding fragments thereof produced by such methods, e.g., purified preparations of secukinumab, wherein the level of intact IL-17 antibodies or antigen binding fragments thereof (e.g., secukinumab) in the preparation is high, e.g., at least about 90%, as measured by sodium dodecyl sulfate capillary electrophoresis (CE-SDS), and wherein the level of activity of IL-17 antibodies or antigen binding fragments thereof (e.g., secukinumab) in the preparation is high, e.g., at least about 92%, as measured by cation exchange chromatograph (CEX).
    Type: Application
    Filed: December 21, 2015
    Publication date: December 28, 2017
    Inventors: Markus Heitzmann, Johann Winkler
  • Publication number: 20170369568
    Abstract: The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.
    Type: Application
    Filed: August 14, 2017
    Publication date: December 28, 2017
    Applicant: E. R. SQUIBB & SONS, L.L.C.
    Inventors: Alison Witte, Denise Williams, Josephine M. Cardarelli, David J. King, David B. Passmore
  • Publication number: 20170369569
    Abstract: Provide is an anti-active GIP antibody which allows accurate detection of active GIP. The present invention provides an anti-active GIP antibody which binds to active GIP and does not substantially bind to nonactive GIP, the antibody recognizing at least one or more amino acids selected from the group consisting of amino acids at 8th to 10th position of the amino acid sequence represented by SEQ ID NO: 5, and comprising, in an H chain, a region comprising the following amino acid sequence (1) or a conservative sequence modification thereof: EMNPSDGRTHFNE (1).
    Type: Application
    Filed: December 21, 2015
    Publication date: December 28, 2017
    Applicant: Kao Corporation
    Inventors: Daisuke FUKUOKA, Noriko OSAKI, Akira SHIMOTOYODOME
  • Publication number: 20170369570
    Abstract: The present invention includes, among other things, ?-1,6-glucan linked to an antibody directed to a cell present in a tumor microenvironment. T regulatory cells can be one type of cell present in the tumor microenvironment. In particular embodiments, the antibody is directed to a surface feature of a T regulatory cell, MDSC, or other immune cell. In certain embodiments, the antibody is directed to T regulatory cells, MDSCs, or other immune cells present in a tumor microenvironment. Compositions including ?-1,6-glucan linked to an antibody directed to a T regulatory cell, MDSC, or other immune cell may be useful, e.g., in the treatment of a tumor or cancer in a subject in need thereof. Accordingly, the present invention provides, among other things, methods and compositions for treatment of a tumor or cancer.
    Type: Application
    Filed: January 20, 2016
    Publication date: December 28, 2017
    Inventors: Ifat Rubin-Bejerano, Gabriel Oscar Reznik, Zuzana Dostalova, Isabelle Sansal-Castellano
  • Publication number: 20170369571
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: June 5, 2017
    Publication date: December 28, 2017
    Applicant: ABBVIE STEMCENTRX LLC
    Inventors: LAURA SAUNDERS, SCOTT J. DYLLA, ORIT FOORD, ROBERT A. STULL, MICHAEL TORGOV, HUI SHAO, DAVID LIU
  • Publication number: 20170369572
    Abstract: Provided herein are compositions, methods and uses involving antibodies that specifically bind to human CD47. Also provided are uses and methods, such as therapeutic methods, diagnostic methods, and methods of making such antibodies.
    Type: Application
    Filed: December 28, 2015
    Publication date: December 28, 2017
    Applicant: CELGENE CORPORATION
    Inventors: Aaron SATO, Ryan STAFFORD, Junhao YANG
  • Publication number: 20170369573
    Abstract: Monomeric Fc-domains are provided, as well as multimeric and single chain proteins comprising the monomeric Fc-domains. The proteins have utility in the treatment of disease. Included, inter glia, are multi specific polypeptides.
    Type: Application
    Filed: January 4, 2016
    Publication date: December 28, 2017
    Inventor: LAURENT GAUTHIER
  • Publication number: 20170369574
    Abstract: An immunotoxin for use in the treatment of leishmaniasis A wherein the immunotoxin comprises a portion which is specifically binding to the cellular surface receptor CD64 as a component A and a cell killing portion as a component B, wherein the cell killing portion alters the function, gene expression, or viability of a cell thereby killing Leishmania-infected macrophages and by this eliminates Leishmania.
    Type: Application
    Filed: January 21, 2016
    Publication date: December 28, 2017
    Applicant: FRAUNHOFER-GESELLSCHAFT ZUR FĂ–RDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
    Inventors: Stefan Barth, Theophilus Thepen, Manoel Barral-Netto, Aldina Barral, Johan Van Weyenbergh
  • Publication number: 20170369575
    Abstract: Disclosed herein are single chain variable fragment CD3 binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a single chain variable fragment CD3 binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are provided.
    Type: Application
    Filed: September 14, 2017
    Publication date: December 28, 2017
    Inventors: Robert B. DUBRIDGE, Pui SETO, Richard J. AUSTIN, Luke EVNIN, Jeanmarie GUENOT, Bryan D. LEMON
  • Publication number: 20170369576
    Abstract: The present disclosure is directed to compositions and methods for the prevention, treatment, and/or functional cure of HIV infection. One aspect of the present disclosure relates to monoclonal antibodies directed against CD4, compositions thereof, and methods employing such compositions for the prevention, treatment, and functional cure of HIV infection.
    Type: Application
    Filed: November 11, 2014
    Publication date: December 28, 2017
    Applicant: UBI US HOLDINGS, LLC.
    Inventor: Chang Yi WANG
  • Publication number: 20170369577
    Abstract: Disclosed are recombinant CD74 polypeptides mutated relative to the naturally occurring CD74 polypeptides with improved properties such as binding of CD74 ligands such as MIF and RTL1000 as well as polynucleotides that encode the polypeptides, expression vectors comprising the polynucleotides, bacteria that include the expression vectors, and methods of making the recombinant polypeptides.
    Type: Application
    Filed: June 21, 2017
    Publication date: December 28, 2017
    Applicants: Oregon Health & Science University, The United States Government as Represented by the Department of Veterans Affairs
    Inventors: Roberto Meza-Romero, Gil Benedek, Arthur A. Vandenbark
  • Publication number: 20170369578
    Abstract: Methods and compositions described herein are useful for rejuvenating skeletal muscle stem cells (i.e., satellite cells), promoting skeletal muscle regeneration, improving exercise endurance, regenerating skeletal muscle degeneration associated with an age-related disorder of skeletal muscle, and treating, preventing, or reversing skeletal muscle conditions.
    Type: Application
    Filed: June 27, 2017
    Publication date: December 28, 2017
    Inventors: Chen-Ming FAN, Michelle ROZO, Liangji LI
  • Publication number: 20170369579
    Abstract: High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13R?1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13R?1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13R?1-mediated activities are also disclosed.
    Type: Application
    Filed: September 6, 2017
    Publication date: December 28, 2017
    Inventors: Andrew Donald Nash, Manuel Baca, Louis Jerry Fabri, Dennis Zaller, William R. Strohl, Zhiqiang An
  • Publication number: 20170369580
    Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.
    Type: Application
    Filed: September 11, 2017
    Publication date: December 28, 2017
    Inventors: Cindy A. Sprecher, Joseph Leon Kuijper, Maria M. Dasovich, Francis J. Grant, Theodore E. Whitmore, Angela K. Hammond, Julia E. Novak, Jane A Gross, Stacey R. Dillon
  • Publication number: 20170369581
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.
    Type: Application
    Filed: February 19, 2015
    Publication date: December 28, 2017
    Inventors: Karen SILENCE, Peter ULRICHTS, Johannes Joseph Wilhelmus DE HAARD, Torsten DREIER, Michael John Scott SAUNDERS, Harald WAJANT, Sofie Maria Elvire GABRIELS, Mahan MOSHIR
  • Publication number: 20170369582
    Abstract: An antibody or a fragment thereof directed against an epitope including or being constituted by at least six contiguous amino acids in the SEQ ID NO: 1 or a conformational epitope comprising or being constituted by at least six amino acids of SEQ ID NO: 1 which are always in the order of the sequence, and its use for the prognosis and/or the diagnosis of a cancer.
    Type: Application
    Filed: January 14, 2016
    Publication date: December 28, 2017
    Inventors: Bertrand HUARD, Pascal SCHNEIDER
  • Publication number: 20170369583
    Abstract: The invention provides methods of treating lupus in a patient with an anti-CD52 antibody. Also includes are methods of increasing infiltration of regulatory T cells to affected sides of the patient's body, methods of reducing urine protein and/or albumin levels and methods of depleting lymphocytes to alleviate lupus symptoms.
    Type: Application
    Filed: March 1, 2017
    Publication date: December 28, 2017
    Applicant: GENZYME CORPORATION
    Inventors: Johanne M. Kaplan, Bruce L. Roberts, William M. Siders
  • Publication number: 20170369584
    Abstract: Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
    Type: Application
    Filed: June 5, 2017
    Publication date: December 28, 2017
    Inventors: Clark PAN, Huawei QIU, Pradeep DHAL, Bo CHEN, Diego GIANOLIO
  • Publication number: 20170369585
    Abstract: Polypeptides and proteins that specifically bind to and immunologically recognize CD276 are disclosed. Chimeric antigen receptors (CARs), anti-CD276 binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.
    Type: Application
    Filed: September 8, 2017
    Publication date: December 28, 2017
    Inventors: Rimas J. Orentas, Zhongyu Zhu, Crystal L. Mackall, Dimiter S. Dimitrov, Bradley St. Croix, Saurabh Saha
  • Publication number: 20170369586
    Abstract: The invention provides antibodies that specifically bind to human CD134. Anti-human CD134 antibodies specifically bind to the extracellular domain of human CD134, including non-OX40 ligand (OX40L) binding domains on human CD134, which is expressed on e.g. activated human conventional effector CD4 and/or CD8 T lymphocytes (Teffs) and on activated human suppressive regulatory CD4 T lymphocytes (Tregs). Humanized anti-human CD134 antibodies are useful (e.g. to empower Teffs anti-cancer effector function and/or to inhibit Tregs suppressive function) for cancer treatment.
    Type: Application
    Filed: September 11, 2017
    Publication date: December 28, 2017
    Inventors: Petrus Johannes SIMONS, Louis BOON, Jinquan LUO, Randall BREZSKI, Monica GOLDBERG
  • Publication number: 20170369587
    Abstract: A bispecific tetravalent antibody comprising an IgG having a pair of heavy chains and a pair of light chains, and two scFv components being connected to either C or N terminals of the heavy or light chains. The bispecific tetravalent antibody may have a binding specificity for two different epitopes on HER2 receptor.
    Type: Application
    Filed: December 19, 2015
    Publication date: December 28, 2017
    Inventors: Zeren Gao, Yi Zhu, Phil Tan, Blair R. Renshaw, Brian R. Kovacevich
  • Publication number: 20170369588
    Abstract: The present invention relates to an antibody capable of binding with high-affinity and high selectivity to the ectodomain of the transmembrane proteoglycan (PG) NG2/CSPG4, preferably to discrete isoforms of said PG, preferably isoforms that may be generated by alternative splicing, and/or coding single nucleotide polymorphisms, and/or post-transcriptional and/or post-translational modifications. The invention further relates to an anti-NG2/CSPG4 antibody possessing the ability to uniquely induce programmed cell death, exhibited as both canonical caspase-dependent apoptosis and authophagy, in NG2/CSPG4-expressing cancer cells. This action being manifested irrespectively of the coaction of other exogenously added factors. Moreover, the present invention refers to a composition comprising the antibody of the invention, in its naked, encapsulated or genetically engineered form, as pharmaceutical excipient.
    Type: Application
    Filed: December 23, 2015
    Publication date: December 28, 2017
    Applicant: UNIVERSITA' DEGLI STUDI DI PARMA
    Inventors: Roberto Perris, Alice Dallatomasina, Pier Andrea Nicolosi, Elisa Tamburini, Maria Teresa Mucignat
  • Publication number: 20170369589
    Abstract: The disclosure relates to binding members, especially antibody molecules, which bind to human Maf. The binding members are useful for the determination of the expression level of Maf.
    Type: Application
    Filed: December 11, 2015
    Publication date: December 28, 2017
    Applicant: INBIOMOTION S.L.
    Inventors: Roger GOMIS, Juan Carlos TERCERO
  • Publication number: 20170369590
    Abstract: Bispecific antibodies which comprise antigen-binding regions binding to two different epitopes of human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods of preparing and using the antibodies are also disclosed.
    Type: Application
    Filed: May 18, 2017
    Publication date: December 28, 2017
    Inventors: Bart DE GOEIJ, Patrick VAN BERKEL, Kristin STRUMANE, Aran Frank LABRIJN, Joost J. NEIJSSEN, Joyce I. MEESTERS, Paul PARREN, Janine SCHUURMAN
  • Publication number: 20170369591
    Abstract: The present invention generally relates to the fields of cancer therapy and cancer prevention. More particularly, the present invention generally relates to a diagnostic marker for predicting the efficacy of topoisomerase I (topo I) inhibitors in the treatment of cancers. More specifically, the present invention relates to methods, machines, computer systems, computable readable media and kits which can be used to identify and determine the effectiveness of topoisomerase I (topo I) inhibitors in the treatment of cancers, and in some embodiments, the level of sensitivity or resistance of a tumor cell to a topoisomerase I inhibitor, such as camptothecin (CPT), or CTP analogues such as topotecan and irinotecan and derivatives thereof.
    Type: Application
    Filed: March 30, 2017
    Publication date: December 28, 2017
    Applicant: BOSTON MEDICAL CENTER CORPORATION
    Inventor: Ajit BHARTI
  • Publication number: 20170369592
    Abstract: Provided are novel human-derived antibodies specific for Fibroblast Activation Protein (FAP), preferably capable of selectively inhibiting the enzymatic activity of FAP, as well as methods related thereto. In addition, methods of diagnosing and/or monitoring diseases and treatments thereof which are associated with FAP are provided. Assays and kits related to antibodies specific for FAP are also disclosed. The novel anti-FAP antibodies can be used in pharmaceutical and diagnostic compositions for FAP-targeted immunotherapy and diagnostics.
    Type: Application
    Filed: January 11, 2016
    Publication date: December 28, 2017
    Applicants: Mabimmune Diagostics AG, Neurimmune Holding AG, University of Zurich
    Inventors: Chad BROKOPP, Jan GRIMM, Benoit COMBALUZIER, Mareike GOERANSON, Christine LOHMANN, Simon HOERSTRUP, Roger NITSCH
  • Publication number: 20170369593
    Abstract: A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that present a choice of two human light chain variable gene segments such that the immunoglobulin light chains expresses by the mouse comprise one of the two human light chain variable gene segments. Methods for making bispecific antibodies having universal light chains using mice as described herein, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, and host cells are provided.
    Type: Application
    Filed: September 11, 2017
    Publication date: December 28, 2017
    Inventors: John McWhirter, Lynn Macdonald, Sean Stevens, Andrew J. Murphy
  • Publication number: 20170369594
    Abstract: Bispecific antibodies which comprise one antigen-binding region binding to an epitope of human epidermal growth factor receptor 2 (HER2) and one antigen-binding region binding to human CD3, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods for preparing and using the antibodies are also disclosed.
    Type: Application
    Filed: May 18, 2017
    Publication date: December 28, 2017
    Inventors: Joost J. NEIJSSEN, Joyce I. MEESTERS, Bart DE GOEIJ, Aran Frank LABRIJN, Paul PARREN, Janine SCHUURMAN
  • Publication number: 20170369595
    Abstract: The present invention relates to multispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies and uses thereof.
    Type: Application
    Filed: June 2, 2017
    Publication date: December 28, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: ULRICH BRINKMANN, WOLFGANG SCHAEFER, KLAUS MAYER
  • Publication number: 20170369596
    Abstract: Provided is a process for reducing the size of ethylcellulose polymer particles comprising (a) providing a slurry comprising (i) water (ii) said ethylcellulose particles, wherein said ethylcellulose polymer particles have D50 of 100 ?m or less; (iii) surfactant comprising 1.2% or more anionic surfactants by weight based on the solid weight of said slurry, with the proviso that if the amount of anionic surfactant is 2.5% or less by weight based on the solid weight of said slurry, then said surfactant further comprises 5% or more stabilizers by weight based on the solid weight of said slurry, wherein said stabilizer is selected from the group consisting of water-soluble polymers, water-soluble fatty alcohols, and mixtures thereof. (b) grinding said slurry in an agitated media mill having a collection of media particles having a median particle size of 550 ?m or smaller. Also provided is a dispersion made by such a process.
    Type: Application
    Filed: December 10, 2015
    Publication date: December 28, 2017
    Inventors: Jorg Theuerkauf, Robert B. Appell, Peter E. Pierini, Christopher J. Tucker
  • Publication number: 20170369597
    Abstract: An industrially scalable process for producing substantially monodisperse compositions of phytoglycogen nanoparticles from phytoglycogen-containing plant materials is provided that avoids the use of chemical, enzymatic or thermo treatments that degrade the phytoglycogen material. Also provided are phytoglycogen nanoparticle compositions produced by these processes.
    Type: Application
    Filed: July 7, 2017
    Publication date: December 28, 2017
    Inventors: Anton KORENEVSKI, Erzsebet PAPP-SZABO, John Robert DUTCHER, Oleg STUKALOV, Rokshana NAZNIN, Khalid MOOMAND